Analysis of Medication in 3925 Outpatient Prescriptions Containing Traditional Chinese Medicine Toosendan Fructus

This study investigates the clinical application and safety of Toosendan Fructus to provide evidence for its rational use in practice. A total of 3,925 outpatient prescriptions containing Toosendan Fructus were collected from January to December 2023 at Guangzhou Hospital of Integrated Chinese and Western Medicine. Data on patient demographics, diagnosis, department distribution, dosage, and herb combinations were analyzed. Among 2,951 patients, 1,697 were female (1.35 times that of male). Most patients (52.18%) were aged 19–44 years. The Liver disease department prescribed the most Toosendan Fructus (28.87%), primarily for liver stagnacy (22.52%). Stir-fried Toosendan Fructus was used in 95.18% of prescriptions, with 64.84% exceeding the Chinese Pharmacopoeia limit (>10 g). Common combinations included Paeoniae Radix Alba, Bupleuri Radix, and vinegar-processed Rhizoma Corydalis. Stir-frying and compatible use of Chinese materia medica can reduce the toxicity of Toosendan Fructus. However, an audit system for off-label use and enhanced medication monitoring are recommended to ensure clinical safety.